Press Releases Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Delayed Nasdaq Other stock markets 12:34:04 2024-05-20 pm EDT			5-day change	1st Jan Change
1.65 ^USD	-7.30%		+13.79%	+39.83%

Apr. 17	Sector Update: Health Care Stocks Retreating Late Afternoon	MT
Apr. 17	Sector Update: Health Care	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma	May. 07	GL
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management	May. 02	NE
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update	Apr. 16	GL
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 19	GL
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors	Feb. 12	GL
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma	Dec. 12	GL
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023	Dec. 11	GL
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management	Nov. 30	NE
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China	Nov. 21	GL
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China	Nov. 21	AQ
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis	Nov. 21	GL
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023	Nov. 20	GL
Connect Biopharma : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	23-10-20	PU
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update	23-09-12	GL
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement	23-09-12	GL
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement	23-09-12	AQ
Connect Biopharma to Participate in Upcoming September Investor Conferences	23-08-24	GL
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology	23-07-10	GL
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum	23-07-05	GL
Connect Biopharma : House Lease Contract - Form 6-K	23-06-23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Press Releases

Filters